ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Panel Recommends Against Pooling Results Of NLST, European Studies, And I-ELCAP. NIH Director Zerhouni To Step Down At End Of October; Six-Year Tenure Brought Many Changes To NIH.

September 26, 2008

Watson To Head Genome Research

September 30, 1988

Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?

September 28, 2012

UCSD Cancer Center Breaks Ground for New Building

November 15, 2002

ORI Final Findings Of Scientific Misconduct

September 16, 1994

NCI RFP Available.

February 18, 2000